8-K - Rhythm Pharmaceuticals, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Rhythm Pharmaceuticals announced on March 19, 2026, that the FDA approved an expanded indication for IMCIVREE (setmelanotide) to reduce excess body weight and maintain reduction long-term in adults and pediatric patients aged 4 years and older with acquired hypothalamic obesity. This marks the first FDA-approved therapy for this rare disease, supported by Phase 3 TRANSCEND trial results showing -18.4% placebo-adjusted BMI reduction.

Key Takeaways

1FDA approved expanded indication for IMCIVREE (setmelanotide) on March 19, 2026, for acquired hypothalamic obesity (HO) in adults and pediatric patients aged 4 years and older.

2Approval based on Phase 3 TRANSCEND trial (N=142) with -18.4% placebo-adjusted BMI reduction at 52 weeks (p<0.0001); setmelanotide arm -15.8% (n=94) vs. placebo +2.6% (n=48).

3First and only FDA-approved therapy for acquired HO, estimated 10,000 patients in U.S.

4Most common adverse reactions (≥20%): skin hyperpigmentation, nausea, vomiting, headache.

5IMCIVREE now also indicated for BBS, POMC/PCSK1/LEPR deficiency (prior approvals).

6Conference call held March 19, 2026, at 5:00 p.m. ET; presentation available at ir.rhythmtx.com.

Current Report Details

Event Type

Regulation Fd

Other Event

Exhibits Only

Disclosure

Voluntary

Variant

8-K

Items Reported

7.01

of this Current Report on Form 8-K (including Exhibits 99.1 and 99.2 attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities E

Regulation Fd

8.01

. Other Events. On March 19, 2026, Rhythm announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for IMCIVREE® (setmelan

Other Event

9.01

. Financial Statements and Exhibits. (d) Exhibits The following Exhibits 99.1 and 99.2 shall be deemed to be furnished and not filed. Exhibit No. Description 99

Exhibits Only

Source Document

Exhibits (3)

8-K

99.1

EX-99.1

99.2

EX-99.2